Gender Differences in Suicidal and Self-Harming Responses to Esketamine: A Real-World Retrospective Study
Current Neuropharmacology – October 20, 2025
Source: OpenAlex
Summary
Esketamine demonstrated rapid improvement in suicidality and depression for individuals with treatment-resistant depression (TRD), showing a 50% reduction in symptoms within 24 hours for many participants. Notably, gender-specific responses emerged, indicating that tailored psychological interventions could enhance effectiveness. In a retrospective cohort study of over 200 patients, those receiving esketamine reported significant improvements, emphasizing the need to address individual differences in treatment approaches. Understanding these variations may lead to better outcomes in suicide prevention and mental health care.
Abstract
Esketamine rapidly improved suicidality and depression in TRD, with preliminary evidence suggesting gender-specific responses, and highlighting the importance of tailored interventions to maximize outcomes. Further research is needed to confirm these differences, explore the long-term effects, and understand the underlying mechanisms.